

# Inflammation Poses a New Target in Diabetes

BY NANCY WALSH  
New York Bureau

NEW YORK — The process of inflammation—increasingly seen as a central component in a wide variety of chronic diseases—may prove to be the link between type 2 diabetes and cardiovascular disease, according to Dr. Vivian Fonseca.

This holds potential implications for the treatment of diabetes, with an old therapeutic approach being revisited. “In 1876, a report appeared in the German literature describing improvement in glucosuria in a patient with diabetes using high doses of sodium salicylate,” Dr. Fonseca said at a meeting sponsored by the American Diabetes Association.

It is now known that low-grade inflammation arises from adipose tissue, with adipocytes secreting many cytokines involved in the production of C-reactive protein, fibrinogen, and metalloproteinases, including tumor necrosis factor- $\alpha$  and interleukin-6 (IL-6).

“The master switch for inflammation is the [nuclear transcription factor] NF-B,

which is normally present in the cytoplasm with [inhibitory protein] IB kinase,” said Dr. Fonseca, professor of medicine and pharmacology, Tulane University, New Orleans.

“When this NF-B/IB axis receives a signal, whether from a virus or from an adipocyte-derived cytokine, NF-B moves into the nucleus, where it serves as a transcription factor for a wide variety of genes involved in the inflammatory process,” he said.

Whether the use of anti-inflammatory agents to interrupt this NF-B axis may rep-

resent a new pharmacologic approach to the treatment of diabetes is now being evaluated in a multicenter study funded by the National Institutes of Health.

The agent being tested is salsalate, which is insoluble at acid pH and therefore does not cause stomach irritation. Salsalate also does not interfere with prostacyclin or cyclooxygenase-2, nor does it raise blood pressure, Dr. Fonseca said.

Preliminary studies with salsalate in a small number of patients have shown that,

aside from suppressing inflammation, it also improves glucose utilization, increases insulin secretion, and increases energy expenditure.

Patients are now being recruited for the study; information is available at [www.tin-sal-t2d.org](http://www.tin-sal-t2d.org).

Dr. Fonseca disclosed that he receives research support from the American Diabetes Association, the National Institutes of Health, and a number of pharmaceutical companies. ■

## Electronic Insulin Protocol Reduces Time, Cuts Errors

ORLANDO — The use of a computer protocol to achieve tight glycemic control dramatically lowered insulin administration errors, compared with a paper-based protocol, according to a study of simulated patients in an intensive care unit.

The computer format also improved satisfaction among ICU nurses, Dr. Anthony Y. Lee of Columbus Children's Hospital in Ohio said at the annual congress of the Society of Critical Care Medicine.

Dr. Lee and colleagues at the University of Maryland Medical Center, Baltimore, recruited 51 medical ICU nurses to complete seven simulated patient scenarios using both the standard paper-based insulin protocol and a computer version of the protocol. The scenarios included a clinical case description, a current insulin dose, and new and previous blood glucose level. The nurses were given standardized instructions on how to use both paper and computer versions of the protocol and were required to indicate the new insulin dose and the time of the next blood glucose check.

The simulated situations produced 357 paper responses and 357 computer responses showing a significant reduction in errors using the computer format. Use of the paper protocol resulted in 82 insulin-dosing errors, compared with 4 errors using the computer system. It seemed that the same study participant committed all four errors using the computer protocol.

Errors in the timing of the next blood glucose check fell from 47 with the paper-based protocol to 8 with the computer format. The time to completion fell from 9 minutes with the paper-based protocol to 6 minutes with the computer program.

—Mary Ellen Schneider

For adult patients with **CHRONIC IDIOPATHIC CONSTIPATION**

## Relief takes a different direction



Targeted chloride channel activation that delivers

- Up to 71% of patients achieved normal bowel function ( $\geq 3$  SBMs\* per week)<sup>1†</sup>
- Proven long-term safety profile demonstrated in 6-month and 12-month safety studies<sup>2</sup>
- The **ONLY** agent approved for adults with chronic idiopathic constipation that includes those 65 years and older

### Important Safety Information

- AMITIZA is indicated for the treatment of chronic idiopathic constipation in the adult population.
- AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.
- The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
- AMITIZA should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional.
- In clinical trials, the most common adverse event was nausea (31%). Other adverse events ( $\geq 5\%$  of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%).

Relief is defined as  $\geq 3$  SBMs per week.

Please see Brief Summary of Prescribing Information on adjacent page.

\*Spontaneous bowel movements.

<sup>†</sup>In 4-week clinical studies. Placebo: 44%-53%.

References: 1. Data on file, Sucampo Pharmaceuticals, Inc. 2. AMITIZA [package insert]. Bethesda, Md: Sucampo Pharmaceuticals, Inc.; 2006.

©2006 Takeda Pharmaceuticals North America, Inc.

LUB-00424

Printed in U.S.A.

08/06

amitiza™  
lubiprostone  
Way to relief  
[www.amitiza.com](http://www.amitiza.com)